JPX and LINC00641 NcRNAs Expression in Prostate Tissue: a Case-control Study

Overview

Journal Res Pharm Sci

Specialty Chemistry

Date 2021 Sep 15

PMID 34522197

Citations 2

Authors

Roshanak S Sajjadi

Mohammad Hossein Modarressi

Mohammad Amin Tabatabaiefar

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Prostate cancer (PC) is the second most prevalent cancer in men. Prostate-specific antigen (PSA) is the main biomarker for screening PC. An increase in PSA could lead to false-positive results. Thus, more appropriate markers should be investigated. In the present study, JPX and LINC00641 expression levels were measured in tumoral prostate tissue compared with the non-tumor tissue.

Experimental Approach: 43 pairs of prostate tumoral and non-tumor tissue were prepared. The expression levels of JPX and LINC00641 were investigated by RT-qPCR.

Findings/results: Significant upregulation of LINC00641 (2.47 ± 0.5 1.41 ± 0.2) and downregulation of JPX (1.42 ± 0.6 2.83 ± 1.0) were observed in PC tissues compared with the normal tissues (their adjacent non-tumoral tissues).

Conclusion And Implications: Dysregulation of JPX and LINC00641 in PC patients could be used in the future as a prognostic biomarker in PC.

Citing Articles

lncRNA Biomarkers of Glioblastoma Multiforme.

Pokorna M, Cerna M, Boussios S, Ovsepian S, OLeary V Biomedicines. 2024; 12(5).

PMID: 38790894 PMC: 11117901. DOI: 10.3390/biomedicines12050932.

Status of integrin subunit alpha 4 promoter DNA methylation in colorectal cancer and other malignant tumors: a systematic review and meta-analysis.

Jafarpour S, Yazdi M, Nedaeinia R, Vatandoost N, Ferns G, Salehi R Res Pharm Sci. 2023; 18(3):231-243.

PMID: 37593168 PMC: 10427793. DOI: 10.4103/1735-5362.371580.

References

Yoon J, Abdelmohsen K, Gorospe M . Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol. 2012; 425(19):3723-30. PMC: 3594629. DOI: 10.1016/j.jmb.2012.11.024. View

Chew C, Lunardi A, Gulluni F, Ruan D, Chen M, Salmena L . In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. Cancer Discov. 2015; 5(7):740-51. PMC: 4497843. DOI: 10.1158/2159-8290.CD-14-1347. View

Zhang Z, Sun J, Bai Z, Li H, He S, Chen R . MicroRNA-153 acts as a prognostic marker in gastric cancer and its role in cell migration and invasion. Onco Targets Ther. 2015; 8:357-64. PMC: 4322869. DOI: 10.2147/OTT.S78236. View

Li B, Cao X, Weng C, Wu Y, Fang X, Zhang X . HoxA10 induces proliferation in human prostate carcinoma PC-3 cell line. Cell Biochem Biophys. 2014; 70(2):1363-8. DOI: 10.1007/s12013-014-0065-7. View

Farhan M, Wang H, Gaur U, Little P, Xu J, Zheng W . FOXO Signaling Pathways as Therapeutic Targets in Cancer. Int J Biol Sci. 2017; 13(7):815-827. PMC: 5555100. DOI: 10.7150/ijbs.20052. View

Ma W, Wang H, Jing W, Zhou F, Chang L, Hong Z . Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2016; 41(2):163-170. DOI: 10.1016/j.clinre.2016.09.002. View

Phin S, Moore M, Cotter P . Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol. 2013; 3:240. PMC: 3775430. DOI: 10.3389/fonc.2013.00240. View

Liu Y, Yin J, Abou-Kheir W, Hynes P, Casey O, Fang L . MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene. 2012; 32(3):296-306. PMC: 7580497. DOI: 10.1038/onc.2012.58. View

Iczkowski K, Lucia M . Current perspectives on Gleason grading of prostate cancer. Curr Urol Rep. 2011; 12(3):216-22. DOI: 10.1007/s11934-011-0181-5. View

10.

Edlind M, Hsieh A . PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 2014; 16(3):378-86. PMC: 4023363. DOI: 10.4103/1008-682X.122876. View

11.

Velonas V, Woo H, Dos Remedios C, Assinder S . Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013; 14(6):11034-60. PMC: 3709717. DOI: 10.3390/ijms140611034. View

12.

Cheetham S, Gruhl F, Mattick J, Dinger M . Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013; 108(12):2419-25. PMC: 3694235. DOI: 10.1038/bjc.2013.233. View

13.

Jin M, Ren J, Luo M, You Z, Fang Y, Han Y . Long non-coding RNA JPX correlates with poor prognosis and tumor progression in non-small-cell lung cancer by interacting with miR-145-5p and CCND2. Carcinogenesis. 2019; 41(5):634-645. DOI: 10.1093/carcin/bgz125. View

14.

Kashi K, Henderson L, Bonetti A, Carninci P . Discovery and functional analysis of lncRNAs: Methodologies to investigate an uncharacterized transcriptome. Biochim Biophys Acta. 2015; 1859(1):3-15. DOI: 10.1016/j.bbagrm.2015.10.010. View

15.

Wang Z, Li Y, Ahmad A, Banerjee S, Azmi A, Kong D . Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem. 2010; 112(1):78-88. PMC: 3792569. DOI: 10.1002/jcb.22770. View

16.

Liang R, Zhi Y, Zheng G, Zhang B, Zhu H, Wang M . Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization. Onco Targets Ther. 2019; 12:157-168. PMC: 6306053. DOI: 10.2147/OTT.S171957. View

17.

Rigau M, Olivan M, Garcia M, Sequeiros T, Montes M, Colas E . The present and future of prostate cancer urine biomarkers. Int J Mol Sci. 2013; 14(6):12620-49. PMC: 3709804. DOI: 10.3390/ijms140612620. View

18.

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

19.

Han D, Wang M, Ma N, Xu Y, Jiang Y, Gao X . Long noncoding RNAs: novel players in colorectal cancer. Cancer Lett. 2015; 361(1):13-21. DOI: 10.1016/j.canlet.2015.03.002. View

20.

Martens-Uzunova E, Bottcher R, Croce C, Jenster G, Visakorpi T, Calin G . Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2013; 65(6):1140-51. DOI: 10.1016/j.eururo.2013.12.003. View